Ornidazole
Not to be confused with ronidazole.
![]() | |
| Systematic (IUPAC) name | |
|---|---|
|
1-Chloro-3-(2-methyl-5-nitro-1H-imidazol-1-yl)propan-2-ol | |
| Clinical data | |
| Trade names | Xynor |
| AHFS/Drugs.com | International Drug Names |
| Routes of administration | Oral |
| Pharmacokinetic data | |
| Metabolism | Metabolized via the liver, excreted in the Urine and Feces |
| Excretion | 85% of single oral dose is eliminated with 5 days - Urine (63%) and Feces (22%) |
| Identifiers | |
| CAS Number |
16773-42-5 |
| ATC code | G01AF06 (WHO) J01XD03 P01AB03 QP51AA03 |
| PubChem | CID 28061 |
| ChemSpider |
26102 |
| UNII |
62XCK0G93T |
| KEGG |
D05274 |
| ChEBI |
CHEBI:75176 |
| ChEMBL |
CHEMBL1449676 |
| Chemical data | |
| Formula | C7H10ClN3O3 |
| Molar mass | 219.625 g/mol |
| |
| |
| | |
Ornidazole is a drug that cures some protozoan infections. It has been investigated for use in Crohn's disease after bowel resection.[1]
Synthesis is a straightforward reaction between 2-methyl-nitroimidazole and epichlorohydrin under acid catalyst conditions.[2]
References
- ↑ Rutgeerts P, Van Assche G, Vermeire S, et al. (April 2005). "Ornidazole for prophylaxis of postoperative Crohn's disease recurrence: a randomized, double-blind, placebo-controlled trial". Gastroenterology 128 (4): 856–61. doi:10.1053/j.gastro.2005.01.010. PMID 15825069.
- ↑ Hoffer, Max; Grunberg, Emanuel (1974). "Synthesis and antiprotozoal activity of 1-(3-chloro-2-hydroxypropyl)-substituted nitroimidazoles". Journal of Medicinal Chemistry 17 (9): 1019–1020. doi:10.1021/jm00255a026. ISSN 0022-2623.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||
This article is issued from Wikipedia - version of the Saturday, April 02, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.
